Journal: Scientific Reports

Article Title: Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment

doi: 10.1038/s41598-022-07153-z

Figure Lengend Snippet: Summary of MC38, Hepa1–6, CT26 and EMT-6 subcutaneous tumor growth inhibition and % immune cell depletion following treatment for lineage specific depletion either alone (% relative to non-treated control, experiment 1) or in combination with anti-PD-1 antibody treatment (% relative to anti-PD-1 control, experiment 2).

Article Snippet: The murine liver cancer cell line Hepa1-6 and colon cancer cell line CT26 were purchased from Shanghai Institutes for Biological Sciences (China), breast cancer cell line EMT-6 was purchased from ATCC.

Techniques: Inhibition, Control, Liposomes

Journal: Journal of colloid and interface science

Article Title: Cubosomes functionalized with antibodies as a potential strategy for the treatment of HER2-positive breast cancer.

doi: 10.1016/j.jcis.2024.06.091

Figure Lengend Snippet: Fig. 1. Proposed nanotechnological platform for targeting HER2-positive breast cancer cells. (A) Design and components of the panobinostat-loaded cubosomes functionalized with trastuzumab. (B) Panobinostat-loaded immunocubosomes administrated intravenously to treat HER2-positive breast cancer. (C) Cellular uptake, (C1) panobinostat-loaded immunocubosomes internalization by breast cancer cell line expressing HER2 (SKBR3), (C2) interaction between HER2 and trastuzumab, (C3) steps of endocytosis, and (C4) cell death.

Article Snippet: For cells, the L929 mouse fibroblast and 4T1 breast cancer were a generous gift from Prof. Dr. Jean-Christophe Leroux’s laboratory, and the SKBR3 breast cancer was purchased from DSMZ, Germany.

Techniques: Expressing

Journal: Journal of colloid and interface science

Article Title: Cubosomes functionalized with antibodies as a potential strategy for the treatment of HER2-positive breast cancer.

doi: 10.1016/j.jcis.2024.06.091

Figure Lengend Snippet: Fig. 4. Cellular uptake and cytotoxicity assessment of free Panobinostat (Free Pa), blank cubosomes (Cub), panobinostat-loaded cubosomes (CubPa) and panobinostat-loaded immunocubosomes (ICubPa) by L929, 4T1, and SKBR3 cell lines. (A) Fluorescence microscopy images of cellular uptake of Dio-loaded cubo somes and Dio-loaded immunocubosomes by L929, 4T1, and SKBR3 cell lines. The first line represents DAPI staining (nuclei, blue), the second line Dio staining (cytoplasm, green), and the third line the overlay of DAPI and Dio staining. Scale bar 50 μm. (B) Cell viability of L929, 4T1, and SKBR3 cells incubated with free panobinostat, blank cubosomes, and panobinostat-loaded cubosomes for 24 h. (C) Cell viability of L929, 4T1, and SKBR3 cells incubated with free panobinostat, panobinostat-loaded cubosomes, and panobinostat-loaded immunocubosomes for 24 h. (D) Analysis of the effectiveness of treatments by observing cell viability and cell death of SKBR3 cell incubated with free panobinostat, panobinostat-loaded cubosomes, and panobinostat-loaded imunocubosomes for 24 h. (E) Analysis of the selectivity of antibody therapy by observing cell viability and cell death of L929 and SKBR3 cells incubated with panobinostat-loaded imunocubosomes for 24 h. Data are shown as mean ± SD of at least six experiments. *Denotes statistical differences between groups, two-way ANOVA, Tukey *p < 0.05.

Article Snippet: For cells, the L929 mouse fibroblast and 4T1 breast cancer were a generous gift from Prof. Dr. Jean-Christophe Leroux’s laboratory, and the SKBR3 breast cancer was purchased from DSMZ, Germany.

Techniques: Fluorescence, Microscopy, Staining, Incubation